Phase 1 Study of ANAVEX3-71

NCT ID: NCT04442945

Last Updated: 2022-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-03
• Study Completion Date: 2021-10-30

Brief Summary

A first in human phase 1 study in healthy volunteers to assess ANAVEX3-71 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Detailed Description

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and bioavailability of orally administered ANAVEX3-71 in healthy volunteers

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ANAVEX3-71 Oral

Up to four single ascending doses of ANAVEX3-71 administered orally

Group Type: EXPERIMENTAL

ANAVEX3-71

Intervention Type: DRUG

Active oral dose of ANAVEX3-71

Placebo arm Oral

Placebo administered orally

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral placebo

Interventions

ANAVEX3-71

Active oral dose of ANAVEX3-71

Intervention Type: DRUG

Placebo

Oral placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy, male or female between 18 and 55 years of age, inclusive.
• Body mass index (BMI) between 19-28 kg/m2 and within a body weight of ≥ 60 kg and ≤ 120 kg.
• Female subjects must be of non-childbearing potential (defined as postmenopausal for at least 2 years or surgically sterile at least 6 months prior to dosing) or must be using adequate contraception.
• Subject is judged by the investigator to be in generally good health at screening based upon the results of a medical history, physical examination, laboratory profile, and 12-lead electrocardiogram (ECG).
• Non-smoker (no tobacco use within past 3 months).
• Subject is willing to comply with the study protocol, in the investigator's judgement.

Exclusion Criteria

• Subject has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, hematological (including myelosuppression and bleeding disorders) or immunological/autoimmune disorder(s), and/or any condition that could constitute a potential safety risk factor or could alter the absorption, distribution, metabolism or elimination of the study drugs.
• Positive test result on Hepatitis B surface antigen (HBsAg) or is Hepatitis C virus antibody (HCV-Ab) positive or positive HIV-1 and/or -2 serology.
• Subject has a history of chronic alcohol abuse within the last 2 years, or has a positive alcohol test or is known to have excessive alcohol intake.
• History of substance abuse, known drug addiction, or positive test for drugs of abuse.
• Subject has participated in another clinical trial of an investigational drug (or a medical device) within the last 3 months or is currently participating in another trial of an investigational drug (or a medical device).
• Female subject who is pregnant or lactating or planning a pregnancy.
• A history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study (psychosis is to be disqualified).
• Subject has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Anavex Australia Pty Ltd.

INDUSTRY

Sponsor Role: collaborator

Anavex Life Sciences Corp.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Countries

Australia

Other Identifiers

ANAVEX3-71-001

Identifier Type: -

Identifier Source: org_study_id